About Sorrento Therapeutics (NASDAQ:SRNE)
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease. Its preclinical human therapeutic antibodies include antibody drug conjugates, bispecific approaches, and T-Cell Receptor, as well as Chimeric Antigen Receptor-T Cell (CAR-T) for adoptive cellular immunotherapy for the treatment of solid and liquid tumors. It is also involved in the development of T-007, an anti-CD38 CAR-T cellular therapy for the treatment of multiple myeloma, as well as for additional potential indications, such as amyloidosis and graft-versus-host disease; and T-009, an anti-CD123 CAR-T cellular therapy for the treatment of acute myelogenous leukemia. The company has license and collaboration agreement with Les Laboratoires Servier for the development, manufacture, and commercialization of products using its human immuno-oncology anti-PD-1 mAb STI-A1110. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100
Debt
Debt-to-Equity Ratio0.03%
Current Ratio0.38%
Quick Ratio0.38%
Price-To-Earnings
Trailing P/E Ratio-5.31
Forward P/E Ratio-15.51
P/E GrowthN/A
Sales & Book Value
Annual Sales$151.85 million
Price / Sales3.63
Cash Flow$0.2166 per share
Price / Cash27.93
Book Value$2.50 per share
Price / Book2.42
Profitability
EPS (Most Recent Fiscal Year)($1.14)
Net Income$9.13 million
Net Margins29.72%
Return on Equity38.43%
Return on Assets11.15%
Miscellaneous
Employees162
Outstanding Shares91,030,000
Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions
What is Sorrento Therapeutics' stock symbol?
Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."
How were Sorrento Therapeutics' earnings last quarter?
Sorrento Therapeutics (NASDAQ:SRNE) issued its earnings results on Monday, November, 16th. The biopharmaceutical company reported ($0.03) EPS for the quarter. The biopharmaceutical company earned $1.10 million during the quarter, compared to analyst estimates of $1.28 million. Sorrento Therapeutics had a net margin of 29.72% and a return on equity of 38.43%. View Sorrento Therapeutics' Earnings History.
What price target have analysts set for SRNE?
6 brokerages have issued 1 year target prices for Sorrento Therapeutics' shares. Their forecasts range from $7.00 to $40.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $15.3333 in the next twelve months. View Analyst Ratings for Sorrento Therapeutics.
Are investors shorting Sorrento Therapeutics?
Sorrento Therapeutics saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 11,895,206 shares, an increase of 45.4% from the March 15th total of 8,183,478 shares. Based on an average daily volume of 5,887,663 shares, the days-to-cover ratio is presently 2.0 days. Approximately 18.2% of the shares of the company are sold short.
Who are some of Sorrento Therapeutics' key competitors?
Some companies that are related to Sorrento Therapeutics include Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Pieris Pharmaceuticals (PIRS), Viralytics (VRACY), Eloxx Pharmaceuticals (ELOX), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International (DYAI), Vitality Biopharma (VBIO), Cleveland BioLabs (CBLI), BIOQUAL (BIOQ) and U.S. Stem Cell (USRM).
Who are Sorrento Therapeutics' key executives?
Sorrento Therapeutics' management team includes the folowing people:
- Dr. Henry H. Ji Ph.D., Co-Founder, Chairman, CEO & Pres (Age 54)
- Mr. George K. Ng Esq., J.D., Exec. VP, Chief Admin. Officer & Chief Legal Officer (Age 44)
- Dr. Jerome Bernard Zeldis M.D., Ph.D., Chief Medical Officer and Pres of Clinical Research, Medical Affairs & Regulatory (Age 68)
- Mr. Dean Ferrigno CPA, VP of Fin. & Chief Accounting Officer
- Dr. Alexis Nahama D.V.M., VP of Corp. Devel.
Has Sorrento Therapeutics been receiving favorable news coverage?
Media stories about SRNE stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sorrento Therapeutics earned a media sentiment score of 0.24 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 46.05 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Sorrento Therapeutics?
Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sorrento Therapeutics' stock price today?
One share of SRNE stock can currently be purchased for approximately $6.05.
How big of a company is Sorrento Therapeutics?
Sorrento Therapeutics has a market capitalization of $573.48 million and generates $151.85 million in revenue each year. The biopharmaceutical company earns $9.13 million in net income (profit) each year or ($1.14) on an earnings per share basis. Sorrento Therapeutics employs 162 workers across the globe.
How can I contact Sorrento Therapeutics?
Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]
MarketBeat Community Rating for Sorrento Therapeutics (SRNE)
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sorrento Therapeutics (NASDAQ:SRNE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Sorrento Therapeutics in the last 12 months. Their average twelve-month price target is $15.3333, suggesting that the stock has a possible upside of 153.44%. The high price target for SRNE is $40.00 and the low price target for SRNE is $7.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $15.3333 | $15.00 | $13.6667 | $11.6667 |
| Price Target Upside: | 153.44% upside | 118.98% upside | 76.34% upside | 557.28% upside |
Sorrento Therapeutics (NASDAQ:SRNE) Consensus Price Target History
Sorrento Therapeutics (NASDAQ:SRNE) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Sorrento Therapeutics (NASDAQ:SRNE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Sorrento Therapeutics (NASDAQ SRNE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 11.22%
Sorrento Therapeutics (NASDAQ SRNE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/28/2018 | George K Ng | Insider | Buy | 90,000 | $9.95 | $895,500.00 | 1,906,177 |  |
| 2/7/2018 | Abg Management Ltd | Major Shareholder | Sell | 150,000 | $7.19 | $1,078,500.00 | | |
| 2/5/2018 | Abg Management Ltd | Major Shareholder | Sell | 70,721 | $8.00 | $565,768.00 | | |
| 1/30/2018 | Abg Management Ltd | Major Shareholder | Sell | 310,000 | $7.64 | $2,368,400.00 | | |
| 1/24/2018 | Pacific Medtech (Bvi) Ltd Asia | Major Shareholder | Sell | 684,288 | $7.56 | $5,173,217.28 | | |
| 6/15/2017 | Henry Ji | Insider | Buy | 29,001 | $1.81 | $52,491.81 | 139,776 | |
| 6/15/2017 | Jaisim Shah | Director | Buy | 10,002 | $1.79 | $17,903.58 | 112,633 | |
| 4/19/2017 | Abg Management Ltd | Major Shareholder | Buy | 550,000 | $2.00 | $1,100,000.00 | | |
| 4/19/2017 | Henry Ji | CEO | Buy | 100,000 | $2.00 | $200,000.00 | 139,776 | |
| 4/13/2017 | Abg Management Ltd | Major Shareholder | Buy | 2,500,000 | $2.00 | $5,000,000.00 | | |
| 2/22/2017 | Henry Ji | Insider | Buy | 2,000 | $5.60 | $11,200.00 | 39,776 | |
| 2/10/2017 | Henry Ji | Insider | Buy | 20,000 | $5.15 | $103,000.00 | 37,776 | |
| 2/3/2017 | Jerome B Zeldis | Insider | Buy | 10,000 | $5.15 | $51,500.00 | 10,000 | |
| 2/3/2017 | Kevin Herde | VP | Buy | 3,000 | $5.15 | $15,450.00 | 7,000 | |
| 2/3/2017 | Yue Alexander Wu | Director | Buy | 5,000 | $5.15 | $25,750.00 | 5,000 | |
| 6/29/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 3,400 | $5.82 | $19,788.00 | 720,174 | |
| 6/23/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 6,901 | $5.85 | $40,370.85 | 720,174 | |
| 6/15/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 19,836 | $5.87 | $116,437.32 | 720,174 | |
| 6/14/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 53,764 | $6.14 | $330,110.96 | 736,146 | |
| 6/13/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 37,792 | $6.15 | $232,420.80 | 736,146 | |
| 3/7/2016 | Patrick Soon-Shiong | Major Shareholder | Sell | 100,000 | $6.19 | $619,000.00 | 859,238 | |
| 8/26/2015 | Henry Ji | CEO | Buy | 500 | $0.95 | $475.00 | 500 | |
| 8/24/2015 | Henry Ji | CEO | Buy | 8,888 | $12.84 | $114,121.92 | 17,776 | |
| 8/21/2015 | Henry Ji | CEO | Buy | 8,888 | $13.08 | $116,255.04 | 14,888 | |
| 11/10/2014 | Henry Ji | CEO | Buy | 5,999 | $4.83 | $28,975.17 | | |
| 11/7/2014 | Henry Ji | CEO | Buy | 4,000 | $4.56 | $18,240.00 | | |
| 11/6/2014 | Henry Ji | CEO | Buy | 3,000 | $4.53 | $13,590.00 | | |
| 12/5/2013 | Henry Ji | CEO | Buy | 1,000 | $8.92 | $8,920.00 | | |
| 12/4/2013 | Henry Ji | CEO | Buy | 1,000 | $8.54 | $8,540.00 | | |
| 11/25/2013 | Jaisim Shah | Director | Buy | 1,000 | $8.65 | $8,650.00 | | |
| 11/22/2013 | Henry Ji | CEO | Buy | 1,000 | $8.47 | $8,470.00 | | |
| 11/22/2013 | Opko Health, Inc. | Major Shareholder | Sell | 8,471 | $8.50 | $72,003.50 | | |
| 11/21/2013 | George Uy | Insider | Buy | 3,000 | $8.36 | $25,080.00 | | |
| 11/21/2013 | Opko Health, Inc. | Major Shareholder | Sell | 4,269 | $8.53 | $36,414.57 | | |
| 11/20/2013 | Opko Health, Inc. | Major Shareholder | Sell | 17,062 | $8.75 | $149,292.50 | | |
| 11/19/2013 | George Uy | Insider | Buy | 2,031 | $8.61 | $17,486.91 | | |
| 11/19/2013 | Henry Ji | CEO | Buy | 2,000 | $8.59 | $17,180.00 | | |
| 11/19/2013 | Jaisim Shah | Director | Buy | 1,000 | $9.00 | $9,000.00 | | |
| 11/15/2013 | Opko Health, Inc. | Major Shareholder | Sell | 2,710 | $8.75 | $23,712.50 | | |
| 11/14/2013 | Opko Health, Inc. | Major Shareholder | Sell | 1,900 | $8.75 | $16,625.00 | | |
| 11/13/2013 | Opko Health, Inc. | Major Shareholder | Sell | 13,457 | $8.75 | $117,748.75 | | |
| 11/8/2013 | Opko Health, Inc. | Major Shareholder | Sell | 2,000 | $8.75 | $17,500.00 | | |
| 11/7/2013 | Opko Health, Inc. | Major Shareholder | Sell | 120,380 | $9.03 | $1,087,031.40 | | |
(Data available from 1/1/2013 forward)
Sorrento Therapeutics (NASDAQ SRNE) News Headlines
| Source: |
|
Sorrento Therapeutics (NASDAQ:SRNE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sorrento Therapeutics (NASDAQ:SRNE) Income Statement, Balance Sheet and Cash Flow Statement
Sorrento Therapeutics (NASDAQ SRNE) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
